The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase III trial of first-line treatment with gemcitabine plus docetaxel versus gemcitabine plus paclitaxel in women with metastatic breast cancer (MBC): A comparison of different schedules and treatment.
Lucia Del Mastro
Honoraria - Lilly; Lilly
Alessandra Fabi
No relevant relationships to disclose
Mauro Mansutti
No relevant relationships to disclose
Michele De Laurentiis
Consultant or Advisory Role - Amgen; Eisai; Genomic Health; Pfizer; Roche
Honoraria - Amgen; Celgene; Eisai; Pfizer; Roche
Antonio Durando
No relevant relationships to disclose
Giuseppe Colantuoni
No relevant relationships to disclose
Alberto Zaniboni
No relevant relationships to disclose
Sandro Barni
No relevant relationships to disclose
Domenico Franco Merlo
Research Funding - Lilly
Paolo Bruzzi
Research Funding - Lilly
Ignazia La Torre
Employment or Leadership Position - Lilly
Matteo Ceccarelli
Employment or Leadership Position - Lilly
Gbenga Kazeem
Employment or Leadership Position - Lilly
Paolo Marchi
Employment or Leadership Position - Lilly
Davide Boy
Employment or Leadership Position - Lilly
Marco Venturini
No relevant relationships to disclose
Sabino De Placido
Honoraria - not declared
Research Funding - not declared
Francesco Cognetti
No relevant relationships to disclose